IBI 3026
Alternative Names: IBI-3026Latest Information Update: 30 May 2025
At a glance
- Originator Innovent Biologics
- Class Antineoplastics; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Cytotoxic T lymphocyte stimulants; Natural killer cell stimulants; Programmed cell death 1 receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 09 May 2025 Preclinical trials in Solid tumours in China (Parenteral)
- 28 Apr 2025 Pharmacodynamics and adverse events data from a preclinical study in Solid tumours released by Innovent Biologics
- 25 Apr 2025 Pharmacodynamics and adverse events data from a preclinical trial in Solid tumours presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)